[go: up one dir, main page]

WO2011160845A3 - Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment - Google Patents

Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment Download PDF

Info

Publication number
WO2011160845A3
WO2011160845A3 PCT/EP2011/003110 EP2011003110W WO2011160845A3 WO 2011160845 A3 WO2011160845 A3 WO 2011160845A3 EP 2011003110 W EP2011003110 W EP 2011003110W WO 2011160845 A3 WO2011160845 A3 WO 2011160845A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipoproteins
oxidized phospholipids
antibodies
well
inflammatory conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/003110
Other languages
French (fr)
Other versions
WO2011160845A2 (en
Inventor
Johan FROSTEGÅRD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDIRISTA BIOTECHNOLOGIES AB
Original Assignee
MEDIRISTA BIOTECHNOLOGIES AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEDIRISTA BIOTECHNOLOGIES AB filed Critical MEDIRISTA BIOTECHNOLOGIES AB
Publication of WO2011160845A2 publication Critical patent/WO2011160845A2/en
Publication of WO2011160845A3 publication Critical patent/WO2011160845A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)

Abstract

A method is disclosed for assessing the risk of developing inflammatory conditions, and/or the risk of mortality related thereto, comprising monitoring and/or determining the levels of one or more oxidized phospholipids and lipoproteins, and antibodies thereto, and comparing said levels with predetermined cutoff values, as well as a kit for implementing the method. Also disclosed is a method for treating or decreasing the risk of developing inflammatory conditions, and/or the risk of mortality related thereto, by administering medicaments comprising annexin A5 and/or antibodies to one or more oxidized phospholipids and lipoproteins, as well as bioactive components and/or parts/fragments thereof. Compositions comprising one or more inhibitors of oxidized phospholipids and lipoproteins, as well as bioactive components and/or parts/fragments thereof, as well as compositions comprising one or more conjugates of oxidized phospholipids and lipoproteins, as well as bioactive components and/or parts/fragments thereof, are also disclosed.
PCT/EP2011/003110 2010-06-24 2011-06-24 Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment Ceased WO2011160845A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US35810210P 2010-06-24 2010-06-24
US61/358,102 2010-06-24
US37344110P 2010-08-13 2010-08-13
US61/373,441 2010-08-13
US201161449276P 2011-03-04 2011-03-04
US61/449,276 2011-03-04

Publications (2)

Publication Number Publication Date
WO2011160845A2 WO2011160845A2 (en) 2011-12-29
WO2011160845A3 true WO2011160845A3 (en) 2012-03-15

Family

ID=44358157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/003110 Ceased WO2011160845A2 (en) 2010-06-24 2011-06-24 Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment

Country Status (1)

Country Link
WO (1) WO2011160845A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2711705A1 (en) 2008-12-19 2014-03-26 Medirista Biotechnologies AB Oxidized cardiolipin as a novel pro-inflammatory factor
GB201702144D0 (en) * 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
WO2018220224A1 (en) * 2017-06-02 2018-12-06 Medirista Biotechnologies Ab Lipid-related antigens and antibodies directed against them
US11530259B2 (en) 2018-01-29 2022-12-20 The Regents Of The University Of California Therapies and methods to treat TLR2-mediated diseases and disorders
US20210041448A1 (en) * 2018-04-19 2021-02-11 The University Of Tokyo Method and kit for assisting diagnosis of disease in subject
KR20220131222A (en) * 2019-11-12 2022-09-27 앱센트라 엘엘시 Cancer Treatment Methods and Compositions
WO2023057588A1 (en) * 2021-10-06 2023-04-13 Iltoo Pharma Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
AU2024240129A1 (en) 2023-03-17 2025-10-09 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
CN118011012B (en) * 2024-02-19 2025-01-21 中国科学院昆明动物研究所 LL-37-ApoB-100 biomarker and its application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010069605A2 (en) * 2008-12-19 2010-06-24 Medirista Biotechnologies Ab Oxidized cardiolipin as a novel pro-inflammatory factor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222030A1 (en) 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
DE602005018914D1 (en) 2004-04-15 2010-03-04 Athera Biotechnologies Ab ANNEXIN FOR PREVENTING THE RUPTURE OF THE PLAQUE
HU227970B1 (en) 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
EP2254589B1 (en) 2008-02-22 2017-04-05 Annexin Pharmaceuticals AB Compounds and methods for the prevention or treatment of restenosis
EP2311109A2 (en) 2008-07-06 2011-04-20 Lamos Inc. Split thermo-electric structure and devices and systems that utilize said structure
WO2010043045A1 (en) 2008-10-17 2010-04-22 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010069605A2 (en) * 2008-12-19 2010-06-24 Medirista Biotechnologies Ab Oxidized cardiolipin as a novel pro-inflammatory factor

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
BOZIC B ET AL: "Influence of degraded phosphatidylserine on binding of antiphospholipid antibodies", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, KARGER AG, CH, vol. 112, no. 1, 1 January 1997 (1997-01-01), pages 19 - 26, XP009154521, ISSN: 1018-2438 *
CHAUHAN ABHA ET AL: "Interaction of amyloid beta-protein with anionic phospholipids: Possible involvement of Lys28 and C-terminus aliphatic amino acids", NEUROCHEMICAL RESEARCH, PLENUM PRESS, NEW YORK, US LNKD- DOI:10.1023/A:1007509608440, vol. 25, no. 3, 1 March 2000 (2000-03-01), pages 423 - 429, XP002544972, ISSN: 0364-3190 *
FROSTEGAARD JOHAN: "Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 134, no. 1, 1 January 2010 (2010-01-01), pages 47 - 54, XP002653740, ISSN: 1521-6616, [retrieved on 20090911], DOI: 10.1016/J.CLIM.2009.08.013 *
FROSTEGARD JOHAN ET AL: "Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations", ARTHRITIS & RHEUMATISM, vol. 52, no. 1, January 2005 (2005-01-01), pages 192 - 200, XP002573122, ISSN: 0004-3591 *
GEORGE LEE ET AL: "Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-beta-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site.", PEPTIDES, vol. 23, no. 7, 1 July 2002 (2002-07-01), pages 1249 - 1263, XP055013630, ISSN: 0196-9781 *
HÖRKKÖ S ET AL: "Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.", THE JOURNAL OF CLINICAL INVESTIGATION 1 AUG 1996, vol. 98, no. 3, 1 August 1996 (1996-08-01), pages 815 - 825, XP002573121, ISSN: 0021-9738 *
MIN WAN: "STUDIES ON LEUKOTRIENE B4 AND ALARMINS IN INFLAMMATORY RESPONSES", 20100101, 29 January 2010 (2010-01-29), pages 1 - 2, XP007919285 *
PIERANGELI S S ET AL: "Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice", THROMBOSIS AND HAEMOSTASIS, SCHATTAUER GMBH, DE; US, vol. 71, no. 5, 1 May 1994 (1994-05-01), pages 670 - 674, XP009154455, ISSN: 0340-6245 *
POPE S ET AL: "Oxidative stress and mitochondrial dysfunction in neurodegeneration; cardiolipin a critical target?", BIOCHIMICA ET BIOPHYSICA ACTA. BIOENERGETICS, AMSTERDAM, NL, vol. 1777, no. 7-8, 1 July 2008 (2008-07-01), pages 794 - 799, XP022762298, ISSN: 0005-2728, [retrieved on 20080329], DOI: 10.1016/J.BBABIO.2008.03.011 *
PRATICO DOMENICO ET AL: "Circulating autoantibodies to oxidized cardiolipin correlate with isoprostane F2alpha-VI levels and the extent of atherosclerosis in ApoE-deficient mice: Modulation by vitamin E", BLOOD, vol. 97, no. 2, 15 January 2001 (2001-01-15), pages 459 - 464, XP002573123, ISSN: 0006-4971 *
R. L. BREY ET AL: "2-Glycoprotein 1-Dependent Anticardiolipin Antibodies and Risk of Ischemic Stroke and Myocardial Infarction: The Honolulu Heart Program", STROKE, vol. 32, no. 8, 1 August 2001 (2001-08-01), pages 1701 - 1706, XP055013940, ISSN: 0039-2499, DOI: 10.1161/01.STR.32.8.1701 *
R. ROLLA ET AL: "Antibodies against oxidized phospholipids in laboratory tests exploring lupus anti-coagulant activity", CLINICAL & EXPERIMENTAL IMMUNOLOGY, vol. 149, no. 1, 1 July 2007 (2007-07-01), pages 63 - 69, XP055013579, ISSN: 0009-9104, DOI: 10.1111/j.1365-2249.2007.03404.x *
RUIHUA WU ET AL: "Antibodies Against Cardiolipin and Oxidatively Modified LDL in 50-Year-Old Men Predict Myocardial Infarction", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 17, no. 11, 1 November 1997 (1997-11-01), pages 3159 - 3163, XP009154454, ISSN: 1079-5642 *
SCHLAME M ET AL: "Effect of cardiolipin oxidation on solid-phase immunoassay for antiphospholipid antibodies", THROMBOSIS AND HAEMOSTASIS, SCHATTAUER GMBH, DE; US, vol. 86, no. 6, 1 December 2001 (2001-12-01), pages 1475 - 1482, XP009130858, ISSN: 0340-6245 *
STEGNAR M ET AL: "Prevalence of antiphospholipid antibodies in deep vein thrombosis and their relationship to blood coagulation and fibrinolysis", THROMBOSIS RESEARCH, TARRYTOWN, NY, US, vol. 63, no. 4, 15 August 1991 (1991-08-15), pages 433 - 443, XP022878878, ISSN: 0049-3848, [retrieved on 19910815], DOI: 10.1016/0049-3848(91)90230-T *
THANH-HA LUONG ET AL: "Seasonal Distribution of Antiphospholipid Antibodies", STROKE, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 32, 1 January 2001 (2001-01-01), pages 1707 - 1711, XP007919846, ISSN: 0039-2499 *
TUHRIM S ET AL: "Antiphosphatidyl serine antibodies are independently associated with ischemic stroke", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 53, no. 7, 22 October 1999 (1999-10-22), pages 1523 - 1527, XP009154528, ISSN: 0028-3878 *
TUOMINEN ANU ET AL: "A natural antibody to oxidized cardiolipin binds to oxidized low-density lipoprotein, apoptotic cells, and atherosclerotic lesions.", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY SEP 2006, vol. 26, no. 9, September 2006 (2006-09-01), pages 2096 - 2102, XP002573119, ISSN: 1524-4636 *
VAARALA O ET AL: "Anticardiolipin response in acute infections", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, SAN DIEGO, CA, US, vol. 41, no. 1, 1 October 1986 (1986-10-01), pages 8 - 15, XP022959316, ISSN: 0090-1229, [retrieved on 19861001], DOI: 10.1016/0090-1229(86)90046-2 *
VAARALA OUTI ET AL: "Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 91, no. 1, 1 January 1995 (1995-01-01), pages 23 - 27, XP002573120, ISSN: 0009-7322 *
VAY D ET AL: "Anti-phospholipid antibodies associated with alcoholic liver disease target oxidized phosphatidylserine on apoptotic cell plasma membranes", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 44, no. 1, 1 January 2006 (2006-01-01), pages 183 - 189, XP025053335, ISSN: 0168-8278, [retrieved on 20060101], DOI: 10.1016/J.JHEP.2005.06.010 *
VON LANDENBERG P ET AL: "The combination of different antiphospholipid antibody subgroups in the sera of patients with autoimmune diseases is a strong predictor for thrombosis", IMMUNOBIOLOGY, URBAN UND FISCHER VERLAG, DE, vol. 207, no. 1, 1 January 2003 (2003-01-01), pages 65 - 71, XP004954264, ISSN: 0171-2985, DOI: 10.1016/S0171-2985(04)70166-7 *
ZHOU XINGHUA ET AL: "LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 21, no. 1, 1 January 2001 (2001-01-01), pages 108 - 114, XP002522457, ISSN: 1079-5642 *

Also Published As

Publication number Publication date
WO2011160845A2 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
WO2011160845A3 (en) Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
WO2014124334A3 (en) Transthyretin antibodies and uses thereof
EP3734280B8 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2571503A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER SUFFERING
WO2014031859A3 (en) Compositions and methods relating to blood-based biomarkers of breast cancer
WO2012142498A3 (en) Mif inhibitors and their uses
WO2015006705A3 (en) Micrornas that silence tau expression
WO2012009567A3 (en) Biomarkers for diagnosis of stroke and its causes
EP3077819A4 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2012093361A5 (en)
WO2013123432A3 (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
WO2012149493A3 (en) Hsp90 combination therapy
BR112012025645A2 (en) high mannose glycans.
EP3822352A3 (en) Methods and compositions for modulating apolipoprotein(a) expression
EA201590247A1 (en) ANTIBODIES TO SIGLEC-15
EA201400119A1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT AND THEIR APPLICATION
WO2014169226A3 (en) Methods of diagnosing and treating chronic pain
WO2010087594A3 (en) Cd93 or use of soluble fragment thereof
EP3577458A4 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3281011A4 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012075422A3 (en) Compositions and methods for treating amyloid plaque associated symptoms
MY189930A (en) Glyt1 inhibitors for use in the treatment of hematological disorders
WO2011107382A3 (en) Positive fit of a shaft comprising at least one impeller and method for fixing an impeller to a shaft of a turbocharger
WO2014132052A3 (en) Compound and method for the treatment and diagnosis of neurodegenerative conditions
AU2012313353A8 (en) Screening method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11736274

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11736274

Country of ref document: EP

Kind code of ref document: A2